- Home
- ANTA vs ALDX Comparison
ANTA vs ALDX Comparison
Compare ANTA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | ALDX |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 293.0M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTA | ALDX |
|---|---|---|
| Price | $10.17 | $4.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.50 | $9.50 |
| AVG Volume (30 Days) | 5.3K | ★ 918.8K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 669.18 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $65,033,103.00 | N/A |
| Revenue This Year | $69.27 | N/A |
| Revenue Next Year | $64.32 | $36.25 |
| P/E Ratio | $21.80 | ★ N/A |
| Revenue Growth | ★ 63.28 | N/A |
| 52 Week Low | $8.50 | $1.14 |
| 52 Week High | $27.72 | $7.20 |
Technical Indicators
Market Signals| Indicator | ANTA | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.89 |
| Support Level | N/A | $4.67 |
| Resistance Level | N/A | $5.04 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 11.88 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.